Skip to content
Business
Prognosis

A Key Drug in Fighting Covid Is Now at Risk

Monoclonal antibodies are still the best treatment for some patients

Video player cover image
Biden Says Covid Testing Funds Are Running Low

Monoclonal antibodies were one of the earliest and most effective drugs for fighting Covid-19. Continued production of them is at risk though — jeopardizing the availability of a key tool in fighting the virus.

Some new antiviral pills appear to be extremely effective, which has relegated antibody drugs to niche corners of the market. Funding for U.S. government orders of antibody drugs is also in danger of running out. The Senate announced $10 billion in repurposed Covid spending this week. However, the deal still needs to pass and the White House said that number was not high enough to meet the continued demands of the pandemic.